Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samia Mora

Showing results (31-40 of 260) with videos related to

Pageof 26
Sort By:
JAMA Internal Medicine|February 7, 2017
Risk and Benefit Information and Use of Aspirin-ReplySamia Mora, JoAnn E Manson
Clinical Chemistry|October 18, 2017
Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic LoweringPatrick R Lawler, Samia Mora
Clinical Chemistry|September 14, 2014
Moving beyond mean glycemia: 1,5-anhydroglucitol and microvascular complications of diabetesPatrick R Lawler, Samia Mora
Atherosclerosis|April 9, 2021
Misperceptions and management of risk: Ongoing challenges in women's cardiovascular healthZareen M Farukhi, Samia Mora
Clinical Chemistry|June 18, 2022
The Curious Case of Synergy between Lipoprotein (a), Coronary Calcification, and Cardiovascular Disease RiskZaid I Almarzooq, Samia Mora
Journal of the American College of Cardiology|December 17, 2025
Do Selection Methods and Outcome Definitions in the EHR Affect Model Calibration and Accuracy of the AHA-PREVENT Risk Equations?Aniket Zinzuwadia, Samia Mora, Olga Demler
European Heart Journal|February 27, 2016
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agentsPaul M Ridker, Samia Mora, Lynda Rose, et al.
Clinical Chemistry|December 20, 2008
The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelinesSamia Mora, Kiran Musunuru, Roger S Blumenthal
JAMA|July 25, 2022
Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in WomenChrisandra L Shufelt, Samia Mora, JoAnn E Manson
Advances in Experimental Medicine and Biology|September 8, 2021
Glycosylation and Cardiovascular DiseasesHesam Dashti, Maria Angelica Pabon Porras, Samia Mora
Pageof 26

Showing results (31-40 of 260) with videos related to

Sort By:
Pageof 26
JAMA Internal Medicine|February 7, 2017
Risk and Benefit Information and Use of Aspirin-ReplySamia Mora, JoAnn E Manson
Clinical Chemistry|October 18, 2017
Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic LoweringPatrick R Lawler, Samia Mora
Clinical Chemistry|September 14, 2014
Moving beyond mean glycemia: 1,5-anhydroglucitol and microvascular complications of diabetesPatrick R Lawler, Samia Mora
Atherosclerosis|April 9, 2021
Misperceptions and management of risk: Ongoing challenges in women's cardiovascular healthZareen M Farukhi, Samia Mora
Clinical Chemistry|June 18, 2022
The Curious Case of Synergy between Lipoprotein (a), Coronary Calcification, and Cardiovascular Disease RiskZaid I Almarzooq, Samia Mora
Journal of the American College of Cardiology|December 17, 2025
Do Selection Methods and Outcome Definitions in the EHR Affect Model Calibration and Accuracy of the AHA-PREVENT Risk Equations?Aniket Zinzuwadia, Samia Mora, Olga Demler
European Heart Journal|February 27, 2016
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agentsPaul M Ridker, Samia Mora, Lynda Rose, et al.
Clinical Chemistry|December 20, 2008
The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelinesSamia Mora, Kiran Musunuru, Roger S Blumenthal
JAMA|July 25, 2022
Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in WomenChrisandra L Shufelt, Samia Mora, JoAnn E Manson
Advances in Experimental Medicine and Biology|September 8, 2021
Glycosylation and Cardiovascular DiseasesHesam Dashti, Maria Angelica Pabon Porras, Samia Mora
Pageof 26